InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,186.43
(
0.11%
)
US TECH 100
17,606.80
(
-0.02%
)
Dow Jones
38,872.37
(
0.05%
)
Brent Oil
83.10
(
-0.46%
)
Bitcoin
63,183.56
(
0.03%
)
Post# of 6095
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119585
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 5539

Tuesday, 05/23/2023 4:12:37 AM

Tuesday, May 23, 2023 4:12:37 AM

Post# of 6095
PFE GLP-1 addendum:

Danuglipron is an oral, non-peptide GLP-1 agonist that is one of two similar oral drugs PFE is evaluating—the other one is PF-07081532 (#msg-170749309). Both compounds can be dosed without regard to food, which PFE sees as a material advantage compared to NVO's Rybelsus, which requires a strict fasting protocol (#msg-171530263).

PFE intends to advance only one of these two similar GLP-1 compounds to phase-3; the determination of which one to advance will be made after the completion of the two phase-2b trials for obese patients now in progress.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent PFE News
More PFE News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!